Drug
AL101
AL101 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
100%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
completed250%
terminated125%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_1
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
NCT04973683
terminatedphase_2
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
NCT04461600
completedphase_2
A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
NCT03691207
completedphase_1
A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101
NCT04111666
Clinical Trials (4)
Showing 4 of 4 trials
NCT04973683Phase 1
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
NCT04461600Phase 2
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
NCT03691207Phase 2
A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
NCT04111666Phase 1
A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4